Myeloid Proliferations Associated with Down Syndrome
NCI Definition: Myeloid neoplasms occurring in individuals with Down syndrome. There is an increased risk of acute leukemias in both children and adults with Down syndrome. In particular, the incidence of acute myeloid leukemia in Down syndrome children of less than five years of age is particularly high, it is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation. This group of disorders also includes the entity transient abnormal myelopoiesis which occurs in neonates and is associated with GATA1 gene mutation. 
There is 1 clinical trial for myeloid proliferations associated with down syndrome, of which 1 is open and 0 are completed or closed. Of the trial that contains myeloid proliferations associated with down syndrome as an inclusion criterion, 1 is phase 3 (1 open).
Cytarabine, daunorubicin, and etoposide are the most common interventions in myeloid proliferations associated with down syndrome clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.